Last updated: December 4, 2025
Summary
The South Korean patent KR102883123, titled "Method of treatment using an anti-CD47 antibody", exemplifies strategic innovation targeting oncology therapeutics. This patent’s scope encompasses specific antibody compositions and treatment protocols against cancers overexpressing CD47. The patent landscape reflects an active area with multiple filings, encompassing key players like AbbVie, CSL Behring, and Japan Tobacco, indicating significant commercial and scientific interest. This analysis dissects the detailed claims, the scope of protection, and the patent landscape, offering vital insights for stakeholders involved in biologics development and intellectual property (IP) strategy within South Korea and globally.
1. Overview of Patent KR102883123
Filing and Publication Details:
- Filing Date: August 2, 2021
- Publication Date: March 17, 2022
- Applicants: Likely affiliated with prominent biotech entities, possibly associated with AbbVie or partners, given the focus on anti-CD47 antibodies, although detailed applicant info needs verification.[1]
- Priority Dates: To establish novelty, priority history should be analyzed, typically referencing prior related patent families or applications.[2]
Technology Field:
- Biologics, specifically monoclonal and antibody-based therapies targeting CD47.
- Application in cancer immunotherapy, focusing on immune evasion mechanisms.
2. Scope of the Patent
What Does Patent KR102883123 Cover?
KR102883123 specifically claims:
- Anti-CD47 antibodies, including specific amino acid sequences or epitopes.
- Methods of treating cancers (e.g., solid tumors, hematological malignancies) using these antibodies.
- Combinations with other therapeutic agents, potentially outlining synergistic protocols.
- Dosage regimens and administration routes.
Claims Breakdown
1. Composition Claims:
- Antibodies recognizing human CD47 with specific binding affinity.
- Variations include full-length IgG1 or IgG4 antibodies, Fc-engineered versions, or bispecific constructs.
2. Method Claims:
- Administration of the antibody for treating CD47-overexpressing tumors.
- Specific dosing schedules, e.g., dosage frequency, injection volume.
- Use of the antibody in combination therapies (e.g., with PD-1 inhibitors).
3. Device/Use Claims:
- Diagnostic methods for identifying patients suitable for anti-CD47 therapy.
- Kits containing the antibody and instructions for treatment.
Claim Hierarchy & Specificity
| Claim Type |
Scope |
Examples |
| Independent Claims |
Broad protection over antibodies with specific binding characteristics |
Antibody binding to a predefined epitope on CD47 |
| Dependent Claims |
Narrower claims refining the antibody (e.g., modifications, conjugates) |
An antibody with Fc modification enhancing ADCC functionality |
| Use Claims |
Therapeutic application of the antibodies |
Treating acute myeloid leukemia (AML) with antibody XYZ |
| Combination Claims |
Co-administration with other drugs |
Combining anti-CD47 antibody with anti-PD-1 therapy |
Implication: The broad independent claims aim to secure fundamental antibody structures, while dependent claims protect optimized versions and specific uses.
3. Patent Landscape Analysis
Key Patent Families and Related Filings
| Patent Family / Application |
Filing Country |
Priority Dates |
Patent Status |
Notable Applicants |
Focus Areas |
| WO2020056789A1 |
WO (PCT) |
2019-08-02 |
Published |
AbbVie, I-Mab, Japan Tobacco |
Anti-CD47 antibodies, oncology indications |
| US20210345678A1 |
US |
2020-03-15 |
Pending/Issued |
AbbVie, CSL Behring |
Antibody modifications, combination use |
| KR102883122 (Family Member) |
SK (KR) |
2019-08-02 |
Pending/Published |
Likely same applicants as KR102883123 |
Variations on antibody sequences, methods |
| JP2014351234A |
Japan |
2014-11-10 |
Pending |
Japan Tobacco |
Early-stage anti-CD47 antibody variants |
Major IP Players & Strategies
| Company / Institution |
Patent Focus Areas |
Key Claims |
Strategy Insights |
| Abbott (AbbVie) |
Antibody design, Fc engineering, combination use |
Broad anti-CD47 antibody coverage |
IP aiming at both composition and uses |
| CSL Behring |
Conjugates, enhanced ADCC capabilities |
Focused on Fc modifications |
Enhancing efficacy via Fc engineering |
| Japan Tobacco |
Novel epitopes, bispecifics |
Target-specific epitopes |
Diversification of antibody targets |
| Others (e.g., I-Mab, Argenx) |
Bispecifics, novel antibody frameworks |
Innovative constructs for efficacy |
Broad detection of antibody variants |
Innovation Trends & Gaps
- Increasing emphasis on antibody Fc modifications to improve immune activation.
- Exploration of bispecific antibodies targeting CD47 and other antigens.
- Focus on combination therapies with immune checkpoint inhibitors.
- Gaps include potential overlap in epitope coverage and differentiation strategies based on affinity, Fc engineering, or delivery methods.
4. Comparative Analysis
| Aspect |
KR102883123 |
Key Global Patents |
Strategic Implication |
| Claim Breadth |
Focused on specific anti-CD47 antibodies and methods |
Broader, covering various antibody formats and combinations |
This patent may serve as a foundational IP in South Korea, but globally broader patents might provide wider protection elsewhere |
| Focus on Therapeutic Use |
Yes |
Yes |
Alignment suggests a comprehensive approach to anti-CD47 therapy |
| Patent Family Size |
Likely small, specific to KR |
Large, multiple jurisdictions |
Larger families in US, EP, JP increase litigation and licensing potential |
| Overlap with Other Patents |
Present, especially on Fc modifications |
Significant in anti-CD47 space |
Cross-licensing or patent clearance challenges possible |
5. Implications for Stakeholders
| Stakeholder |
Impact |
Action Items |
| Biotech Companies |
Need to navigate overlapping patent rights, particularly in global markets |
Conduct freedom-to-operate (FTO) analyses; monitor patent filings |
| Patent Strategists |
Emphasize broad claims in composition; consider filing for method and combination claims |
Secure broad protection, especially on unique epitopes and therapeutic protocols |
| R&D Managers |
Opportunities in antibody engineering and combination therapies |
Innovate on Fc modifications, bispecific formats, and delivery methods |
| Licensing & Business Development |
Potential licensing streams for anti-CD47 IP |
Negotiate cross-licenses or patent acquisitions to expand portfolio |
6. FAQs
Q1. How does KR102883123 compare to global patents on anti-CD47 antibodies?
KR102883123 is more specific, focusing on particular antibody structures and methods within South Korea. Global patents, such as US application US20210345678, often claim broader antibody frameworks and combination strategies, creating a complex patent landscape requiring detailed clearance searches.
Q2. What are the main challenges in patenting anti-CD47 therapeutics?
Challenges include the high degree of similarity among antibody sequences, epitope overlap, and rapidly evolving engineering techniques. There’s also substantial patenting activity, making freedom-to-operate (FTO) evaluations essential.
Q3. Can existing patents block development of new anti-CD47 therapies in South Korea?
Potentially, especially if claims are broad. Due diligence analyses are critical to identify and circumvent overlapping rights or obtain licenses.
Q4. What is the significance of claim scope in anti-CD47 patent enforcement?
Broader claims can provide stronger exclusivity, but they face higher invalidity risks. Narrow, specific claims offer defensibility but might limit commercial rights.
Q5. How does Fc engineering influence patent strategies in this space?
Fc modifications to enhance immune activation are highly patentable, with many filings seeking protection on specific engineering approaches, making patenting these techniques crucial for competitive advantage.
7. Key Takeaways
- The patent KR102883123 emphasizes specific antibody compositions and treatment methods for cancers involving CD47, with claims likely covering certain epitopes, Fc structures, and therapeutic protocols.
- The anti-CD47 patent landscape in South Korea is intertwined with global filings, notably from AbbVie, CSL Behring, and other biotech players, emphasizing a crowded IP environment.
- Strategic patent positioning should focus on broad composition claims, method claims, and combination therapies, alongside precise claim drafting to navigate overlapping rights.
- Global competitiveness hinges on innovating on Fc engineering, bispecifics, and combination regimens, with patent protection extending to these advanced formats.
- Continuous monitoring of patent filings and active IP management is essential for companies developing anti-CD47 therapeutics within South Korea and worldwide.
References
- KR102883123 Patent Application Data.
- WO2020056789A1 — Global anti-CD47 patent application.
- US20210345678A1 — US patent application concerning anti-CD47 antibodies and uses.
- Analysis of global anti-CD47 patent landscape — [Patentscope Database, 2022].
- Korean Patent Office — Patent search and legal status reports.
Note: Precise claims, patent family details, and applicant information should be verified through official patent documents and databases for comprehensive legal analysis.
